Section Edited by Howard L. Kaufman, MD, FACS
This section focuses on the role of therapeutic agents designed for targeting tumor cells and/or the tumor microenvironment. This includes oncolytic viruses, microbial agents, innate immune agonists, direct and systemically delivered proteins and DNA/RNA products that act within established tumors. Research describing the characterization and basic biology of oncolytic agents and novel delivery systems are encouraged. An emphasis on how novel intra-tumoral directed agents modulate local and systemic host innate and adaptive anti-tumor immunity are of particular interest. In addition, the section welcomes translational and clinical investigation involving new oncolytic immunotherapy agents or those that include an oncolytic approach as part of combination therapeutic regimens.
Neoadjuvant intratumoral influenza vaccine treatment in patients with proficient mismatch repair colorectal cancer leads to increased tumor infiltration of CD8+ T cells and upregulation of PD-L1: a phase 1/2 clinical trialMikail Gögenur, Lukas Balsevicius, Mustafa Bulut, Nesibe Colak, Tobias Freyberg Justesen, Anne-Marie Kanstrup Fiehn, Marianne Bøgevang Jensen, Kathrine Høst-Rasmussen, Britt Cappelen, Shruti Gaggar, Asma Tajik, Jawad Ahmad Zahid, Astrid Louise Bjørn Bennedsen, Tommaso Del Buono D’Ondes, Hans RaskovSee the full list of authors
12 May 2023
OncoVEXexpands tumor antigen-specific CD8+ T-cell response in preclinical modelsJuan Estrada, Jinghui Zhan, Petia Mitchell, Jonathan Werner, Pedro J Beltran, Jason DeVoss, Jing Qing, Keegan S Cooke
10 May 2023
Vector Aided Microenvironment programming (VAMP): reprogramming the TME with MVA virus expressing IL-12 for effective antitumor activityLaura Seclì, Luigia Infante, Linda Nocchi, Maria De Lucia, Gabriella Cotugno, Guido Leoni, Elisa Micarelli, Irene Garzia, Lidia Avalle, Giulia Sdruscia, Fulvia Troise, Simona Allocca, Giuseppina Romano, Elisa Scarselli, Anna Morena D'Alise
28 April 2023
Safety and efficacy of the tumor-selective adenovirus enadenotucirev, in combination with nivolumab, in patients with advanced/metastatic epithelial cancer: a phase I clinical trial (SPICE)Marwan Fakih, Wael Harb, Daruka Mahadevan, Hani Babiker, Jordan Berlin, Tom Lillie, David Krige, Jo Carter, Chris Cox, Minesh Patel, Lola Parfitt, Mark Powell, Lee Rosen
24 April 2023
Intratumor childhood vaccine-specific CD4 T-cell recall coordinates antitumor CD8 T cells and eosinophilsMichael C Brown, Georgia M Beasley, Zachary P McKay, Yuanfan Yang, Annick Desjardins, Dina M Randazzo, Daniel Landi, David M Ashley, Darell D Bigner, Smita K Nair, Matthias Gromeier
18 April 2023
Ectopic expression of cGAS in Salmonella typhimurium enhances STING-mediated IFN-β response in human macrophages and dendritic cellsLisette Waanders, Lieve E H van der Donk, Louis S Ates, Janneke Maaskant, John L van Hamme, Eric Eldering, Jaco A C van Bruggen, Joanne M Rietveld, Wilbert Bitter, Teunis B H Geijtenbeek, Coenraad P Kuijl
18 April 2023
Development of the oncolytic virus, CF33, and its derivatives for peritoneal-directed treatment of gastric cancer peritoneal metastasesAnnie Yang, Zhifang Zhang, Shyambabu Chaurasiya, Anthony K Park, Audrey Jung, Jianming Lu, Sang-In Kim, Saul Priceman, Yuman Fong, Yanghee Woo
5 April 2023
Cancer cell genotype associated tumor immune microenvironment exhibits differential response to therapeutic STING pathway activation in high-grade serous ovarian cancerNoor Shakfa, Deyang Li, Gwenaelle Conseil, Elizabeth D Lightbody, Juliette Wilson-Sanchez, Ali Hamade, Stephen Chenard, Natasha A. Jawa, Brian J. Laight, Afrakoma Afriyie-Asante, Kathrin Tyryshkin, Martin Koebel, Madhuri Koti
4 April 2023
Adaptation of transgene mRNA translation boosts the anticancer efficacy of oncolytic HSV1Huy-Dung Hoang, Aida Said, Nasana Vaidya, Victoria H Gilchrist, Kyle Malone, Usha Kabilan, Serena Topshee, Xiao Xiang, An-Dao Yang, David Olagnier, Karen Mossman, Shawn T Beug, Seyed Mehdi Jafarnejad, Samuel T Workenhe, Tyson E GraberSee the full list of authors
23 March 2023
PKR induces TGF-β and limits oncolytic immune therapyBangxing Hong, Upasana Sahu, Matthew P Mullarkey, Evan Hong, Guangsheng Pei, Yuanqing Yan, Yoshihiro Otani, Yeshavanth Banasavadi-Siddegowda, Huihui Fan, Zhongming Zhao, Jianhua Yu, Michael A Caligiuri, Balveen Kaur
16 February 2023